Chemotherapy plus immunotherapy before surgery for bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug given before surgery for bile duct cancer. The goal is to see if this approach shrinks tumors and lowers the chance of cancer coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have bile duct cancer that is planned to be removed with surgery.
- You have not had chemotherapy, targeted therapy, or immunotherapy for this cancer before.
- Your cancer has at least one high-risk feature, like a large tumor, lymph node spread, or high CA19-9 levels.
- Your liver and kidney function are within acceptable limits (your doctor can confirm).
- You do not have an active autoimmune disease or need long-term steroid treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial tests a combination of chemotherapy, an immunotherapy drug called adebrelimab, and a supportive medication to shrink bile duct or gallbladder tumors before surgery. The goal is to make the tumor easier to remove and improve outcomes.
This trial tests a combination of drugs given before surgery to shrink bile duct cancer and possibly improve outcomes. The drugs include an immunotherapy (tislelizumab) and three chemotherapy agents (gemcitabine, cisplatin, and S-1).
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (pembrolizumab) given before and after surgery for people with bile duct or gallbladder cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
Hear when a new Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.